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Can [125I]-iodocyanopindolol label β3-adrenoceptors in rat 
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β3-Adrenoceptors have been demonstrated to mediate urinary bladder smooth muscle relaxation 
but proof of their expression at the protein level has been missing because of lack of suitable 
antibodies or radioligands. As among various available radioligands [125I]-iodocyanopindolol 
([125I]-ICYP) exhibited the smallest problems in labeling cloned human β3-adrenoceptors in 
previous studies, we have explored its suitability to label β3-adrenoceptors in rat urinary 
bladder in saturation and competition radioligand binding experiments. Rat lung was used as 
an internal control and exhibited all characteristics expected from this tissue with regard to 
β1/β2-adrenoceptor labeling. Saturation and competition binding studies with [125I]-ICYP in rat 
bladder yielded saturable binding sites with an affinity compatible with β3-adrenoceptors. In 
competition experiments various agonists and antagonists largely exhibited a profile compatible 
with a population consisting largely of β3-adrenoceptors. However, the binding competition 
properties of ICI 118,551 and SR 59,230A were not easily explained by the idea of labeling a 
homogeneous β3-adrenoceptor population but interpretation of the data was limited by a high 
degree of non-specific binding in [125I]-ICYP concentrations required to label the receptors. We 
conclude that [125I]-ICYP can be used to label tissue β3-adrenoceptors but results obtained with 
this ligand have to be interpreted with caution.
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the present study was performed to explore whether [125I]-ICYP 
may be suitable to label β
3
-adrenoceptors in rat urinary bladder 
despite its known short-comings as a radioligand for this receptor 
subtype. Rat lung was used as an internal control in our experi-






All experiments were performed under the German legislation for 
the care of experimental animals. Adult Wistar rats of either gender 
were obtained from the breeding facility at the University of Essen 
Medical School. They were killed by decapitation under light ether 
anesthesia. Lung and bladder were rapidly removed, freed from sur-
rounding connective tissues and rapidly frozen in liquid nitrogen. 
Thereafter, they were stored until use for up to 3 months at −70°C. 
On the day of the experiment, the tissues were thawed in ice-cold 
preparation buffer (50 mM Tris, 10 mM MgCl
2
, 0.5 mM EDTA, pH 
7.5), minced with scissors and homogenized with an Ultra-Turrax 
(Janke & Kunkel, Staufen, Germany) for 10 s at full speed and then 
twice for 20 s each at 2/3 speed. The homogenates were filtered 
through medical gauze and then centrifuged for 20 min at 50,000 g 
at 4°C. The pellets were re-suspended in buffer, re-homogenized 
shortly (10 s at full speed) and washed by an additional centrifuga-
tion step. The final pellets were re-suspended and re-homogenized 
in binding buffer (see below).
introduction
β-Adrenoceptors play an important role in the regulation of uri-
nary bladder function. They do so by promoting smooth mus-
cle relaxation (Michel and Vrydag, 2006) but may also act on 
urothelial mediator release (Otsuka et al., 2008; Masunaga et al., 
2010) and afferent nerve function (Leon et al., 2008; Aizawa et al., 
2010). The receptor mediating bladder smooth muscle relaxation 
in humans, and perhaps also those involved in urothelium and 
afferent nerves, belongs predominantly if not exclusively to the 
β
3
-subtype (Michel and Vrydag, 2006). However, demonstrating 
the presence of this subtype in the bladder or other tissues at the 
protein level has been difficult in the past, specifically because 
commercially available antibodies against this receptor may lack 
the required selectivity (Pradidarcheep et al., 2009) and avail-
able radioligands have only low affinity for the β
3
-adrenoceptor 
(Vrydag and Michel, 2007).
In a recent study, we have compared radioligands for their abil-
ity to label cloned human β-adrenoceptor subtypes, i.e., [3H]-di-
hydroalprenolol, [3H]-CGP 12,177, and [125I]-iodocyanopindolol 
([125I]-ICYP) (Niclauß et al., 2006). While none of them had the 
desired properties for labeling β
3
-adrenoceptors, [125I]-ICYP 
was the most promising among the candidates. [125I]-ICYP is a 





(Engel et al., 1981) but has also been used in other studies for 
the labeling of cloned human (Hoffmann et al., 2004) or rodent 
β
3
-adrenoceptors (Muzzin et al., 1991). Against this background 
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biphasic sigmoidal curves to the experimental data; a biphasic 
fit was accepted only if it resulted in a significant improvement 
of the fit as judged by an F-test. This test was performed for 
each individual experiment and formed the primary basis of 
our analysis as shown in Table 1; in contrast, the figures for 
the competition experiments represent pooled data and hence 
do not allow conclusions about the superiority of 1- vs. 2-site 
fits. Resulting IC
50
 values were converted into K
i
 values by the 
Cheng–Prusoff equation (Cheng and Prusoff, 1973). Data are 
shown as mean ± SEM of n experiments. All curve fitting pro-
cedures were performed with the Prism program (Graphpad 
Software, San Diego, CA, USA).
results
radioligand binding studies rat lung
[125I]-ICYP exhibited saturable high affinity binding in rat lung 
membranes. The number and affinity of the detectable binding sites 
was similar regardless whether 1 μM propranolol or 100 μM iso-
prenaline was used to define non-specific binding in paired experi-
ments (B
max
 251 ± 55 vs. 264 ± 55 fmol/mg protein, K
d
 22.1 ± 4.1 
vs. 21.3 ± 6.2 pM, n = 4 each).
Competition binding experiments were performed in 
rat lung membranes using an [125I]-ICYP concentration of 
82 ± 2 pM (n = 37), which resulted in 24 ± 1% non-specific 
binding. The overall competition profile yielded the expected 
findings (Table 1). Thus, the β
1
-selective antagonist CGP 
20,712A and the β
2
-selective antagonist ICI 118,551 detected 
27 ± 1 and 69 ± 9% high affinity sites, respectively. These 
experiments confirmed that rat lung contains predominantly 





-adrenoceptors, and validate our 
radioligand binding assay. Of note, isoprenaline was the only 
agonist for which competition curves were consistently better 
fit by a two-site model, SR 59,230A had relatively high affin-
ity (pK
i
 7.22 ± 0.04, Figure 1), and non-iodinated cyanopin-
dolol had monophasic competition curves with an affinity (pK
i
 
9.62 ± 0.09, Figure 2).
Radioligand binding assays were performed as previously 
described (Goepel et al., 1997) with minor modifications. 
Briefly, aliquots of the membrane preparations (approxi-
mately 4–10 and 15–30 μg protein per tube for lung and blad-
der, respectively) were incubated in a total volume of 250 μl 
binding buffer (10 mM Tris, 150 mM NaCl at pH 7.4) with 
[125I]-ICYP for 90 min at 37°C. Incubations were terminated 
by rapid vacuum filtration over Whatman GF/C filters using a 
Brandell cell harvester. Filters were washed with approximately 
20 ml ice-cold incubation buffer. Unless otherwise indicated, 
non-specific binding was defined using 100 μM isoprenaline. 
In saturation experiments 6–12 [125I]-ICYP concentrations were 
used, whereas in competition experiments 21 narrowly spaced 
competitor concentrations were used; in every case each data 
point was assessed in duplicate.
cheMicals
[125I]-ICYP (specific activity 2200 Ci/mmol) was obtained from 
New England Nuclear (Dreieich, Germany). (−)-Adrenaline 
bitartrate, BRL 37,344 ((±)-R*,R*)-[4-[2-[[2-(3-chlorophenyl)-
2-hydroxyethyl]amino]propyl]phenoxy]-acetic acid sodium), 
(±)-CGP 12,177 (4-[3-[(1,1-dimethylethyl)amino]-2-
hydroxypropoxy]-1,3-dihydro-2H-benzimidazol-2-one hydro-
chloride), CGP 20,712A (1-[2-((3-carbamoyl-4-hydroxy)phenoxy)
ethylamino]-3-[4-(1-methyl-4-trifluoromethyl-2-imidazolyl)
phenoxy]-2-propanol methanesulfonate), S-(-)-cyanopindolol, 
ICI 118,551 ((±)-1-[2,3-(dihydro-7-methyl-1H-inden-4-yl)oxy]-
3-[(1-methylethyl)amino]-2-butanol), (−)-isoprenaline hydro-
chloride, (−)-noradrenaline bitartrate, (±)-propranolol HCl and 
SR 59,230A (3-(2-ethylphenoxy)-[(1S)-1,2,3,4-tetrahydronaphth-
1-ylamino]-(2S)-2-propanol oxalate) were obtained from Sigma-
Aldrich (Munich, Germany).
data analysis
Saturation binding data were analyzed by fitting rectangular 
hyperbolic functions to the experimental data. Competition 
binding experiments were analyzed by fitting mono- and 
Table 1 | Estimated drug affinities in rat lung and urinary bladder.
 Lung Bladder
 pKi high pKi low % High affinity sites n pKi high pKi low % High affinity sites n
Adrenaline – 5.48 ± 0.39 – 3 – 5.15 ± 0.07 – 4
Noradrenaline – 5.58 ± 0.39 – 3 – 5.50 ± 0.15 – 4
Isoprenaline 8.31 ± 0.76 5.87 ± 0.07 29 ± 9 3 8.18 ± 0.13 5.09 ± 0.14 22 ± 8 4
BRL 37,344 – 5.87 ± 0.06 – 4 – 5.10 ± 0.72 – 4
CGP 12,177 – 10.05 ± 0.04 – 3 – 6.78 ± 0.33 – 7
Propranolol – 8.29 ± 0.02 – 3 – 5.86 ± 0.29 – 4
CGP 20,712A 8.43 ± 0.15 4.90 ± 0.04 27 ± 1 3 – 5.59 ± 0.30 – 4
ICI 118,551 8.42 ± 0.21 6.74 ± 0.21 69 ± 9 5 8.92 ± 0.67 5.76 ± 0.42 39 ± 14 4
SR 59,230A – 7.22 ± 0.04 – 4 – 5.66 ± 0.07 – 4
Cyanopindolol – 9.62 ± 0.09 – 6 – 6.97 ± 0.49 – 8
Data are mean ± SEM of n experiments. Results from a biphasic function are shown only if this resulted in a significantly better fit than a monophasic function as 
judged by an F-test. Note that SR 59,230A competed for more binding sites in bladder membranes than any of the other agents (Figure 1). Note also that competition 
curves of cyanopindolol were very shallow in rat bladder membranes but not consistently better explained by a two-site model (Figure 2).
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than those in rat lung and are mainly propranolol-resistant, i.e., 




-adrenoceptors. Based on these data, all 
further experiments were performed with definition of non-specific 
binding by 100 μM isoprenaline.
In light of the lower [125I]-ICYP affinity in the saturation binding 
experiments, competition binding in rat bladder was performed 
using an [125I]-ICYP concentration of 567 ± 1 pM (n = 62), which 
resulted in 63 ± 2% of non-specific binding. The competition curves 
for most compounds in rat bladder membranes were best explained 
by monophasic fits with all competitors exhibiting relatively low 
affinity, i.e., less than 1 μM (Figure 4; Table 1). Only CGP 12,177 
and cyanopindolol had slightly higher affinity, and only the agonist 
isoprenaline (but not any of the other agonists) and the β
2
-selective 
antagonist ICI 118,551 yielded biphasic competition curves, the lat-
ter having 39% high affinity sites. Two other competitors exhibited 
noteworthy behavior: While SR 59,230A had monophasic compe-
tition curves, it competed for far more [125I]-ICYP binding sites 
than any of the other test compounds and specifically for much 
more than the isoprenaline concentration used for the definition 
of non-specific binding (Figure 1). Non-iodinated cyanopindolol 
exhibited very shallow competition curves (Hill-slope 0.46 ± 0.06, 
n = 8; Figure 2) but only in 3 out of 8 experiments these were 




-Adrenoceptors have been implicated mediating various tis-
sue functions, but detection of corresponding receptor protein 
expression has been difficult in the past due to lack of suitable 
antibodies or radioligands (Michel et al., 2010). While none of 
the available radioligands has optimal properties for the labe-
ling of β
3
-adrenoceptors, our previous studies (Niclauß et al., 
2006) in line with data from other investigators (for review see 
Vrydag and Michel, 2007) have demonstrated that if anything 
[125I]-ICYP may be suitable to label β
3
-adrenoceptors in tis-
sues. Indeed, [125I]-ICYP has been used in one previous study 
radioligand binding studies rat bladder
In contrast to the above findings in rat lung, the amount of specific 
binding in rat bladder defined by 100 μM isoprenaline appeared to 
be much greater than that defined by 1 μM propranolol in paired 
experiments, the latter yielding almost no “specific” binding (data 
not shown). Even when non-specific binding was defined using 
100 μM isoprenaline, specific [125I]-ICYP binding to the membrane 
preparation from rat urinary bladder did not approach satura-
tion in concentrations up to 150 pM (data not shown). Therefore, 
we performed additional saturation experiments with [125I]-ICYP 
concentrations up to 1200 pM defining non-specific binding by 
100 μM isoprenaline (Figure 3). Under these conditions a B
max
 of 
149 ± 52 fmol/mg protein and a K
d
 of 579 ± 147 pM (n = 6) were 
found. In paired experiments in the additional presence of 1 μM 
propranolol (definition of non-specific binding also with 100 μM 
isoprenaline), estimates of B
max
 (222 ± 111 fmol/mg protein) and 
K
d
 (562 ± 196 pM) were very similar to those determined in the 
absence of propranolol. These experiments established that [125I]-
ICYP binding sites in rat bladder have considerably lower affinity 
FIgurE 3 | [125I]-ICYP saturation binding in rat urinary bladder. Non-
specific binding was defined by 100 μM isoprenaline, and experiments were 
performed in the absence (control) and presence of 1 μM propranolol. Data 
are from a representative experiment which was performed 6 times with 
similar results (see text for mean results).
FIgurE 1 | Competition for [125I]-ICYP binding to rat lung (open circles) and 
urinary bladder (filled squares) by Sr 59,320A. Data are mean ± SEM of 4 
experiments. Note that SR 59,230A competes for more than 100% of all specific 
sites as defined by 100 isoprenaline. Quantitative results are shown in Table 1.
FIgurE 2 | Pseudo-homologous competition binding of non-iodinated 
cyanopindolol for [125I]-ICYP in rat lung (open circles) and urinary bladder 
membranes (filled squares). Data are mean ± SEM of 6 to 8 experiments. Of 
note the competition curves in bladder membranes were very shallow but 
only in 3 out of 8 experiments were significantly better fitted by a two-site 
model. Quantitative results are shown in Table 1.
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Our experiments in rat urinary bladder yielded a very different 
picture. Within the concentration range of [125I]-ICYP yielding 
receptor saturation in rat lung (up to 150 pM), little specific binding 
was detected in the bladder. However, saturable specific binding was 
detectable at higher concentrations. The corresponding K
D
 value 
(579 pM) was in line with previously reported [125I]-ICYP affinities 
at cloned human and rat β
3
-adrenoceptors but much higher than 




-adrenoceptors (Muzzin et al., 1991; 
Hoffmann et al., 2004). Performing the [125I]-ICYP saturation 





; while this concentration of propranolol 
yields little occupancy of β
3





-adrenoceptors (Hoffmann et al., 2004). Therefore, our saturation 
binding isotherms provided preliminary evidence that [125I]-ICYP 
predominantly if not exclusively labeled β
3
-adrenoceptors in rat 
urinary bladder. Accordingly, this saturable [125I]-ICYP binding 
was detectable only if non-specific binding was defined by 100 μM 
isoprenaline and not when it was defined by 1 μM propranolol, 





-tissue rat lung. The density of the specific [125I]-ICYP 
binding sites in rat bladder (approximately 150–200 fmol/mg pro-
tein) was in line with the total β-adrenoceptor expression density 
in many other tissues. Of note, [125I]-ICYP can also bind to some 
subtypes of 5-HT receptors (Hoyer et al., 1985), but as we defined 
non-specific binding by the β-adrenoceptor agonist isoprenaline 
and because isoprenaline exhibited the expected affinity for binding 
to β-adrenoceptors potential [125I]-ICYP binding to 5-HT receptors 
is unlikely to have contributed to our specific binding. However, 
it may be part of the large non-specific binding reported here for 
the rather high [125I]-ICYP concentrations required to label the 
β
3
-adrenoceptors. The relative contribution of 5-HT receptors to 
the non-specific binding may differ between tissues and cell types 
according to their expression of such receptors. However, the obser-
vation that the high concentrations of [125I]-ICYP required to label 
the β
3
-adrenoceptors is similarly seen in various cell types includ-
ing those lacking 5-HT receptors such as Chinese hamster ovary 
(Niclauß et al., 2006) or human embryonic kidney cells (Vrydag 
et al., 2009) suggests that most of the non-specific binding is indeed 
non-specific rather than to 5-HT receptors.
Competition experiments were performed with various 
β-adrenoceptor agonists and antagonists to obtain a more com-
prehensive characterization of the ligand recognition profile of 
the [125I]-ICYP binding sites. The endogenous catecholamines 
noradrenaline and adrenaline and the prototypical β-adrenoceptor 
agonist isoprenaline had affinities in rat bladder which were in line 





of noradrenaline) and also with the reported values at all human 
β-adrenoceptor subtypes (Hoffmann et al., 2004). Most impor-
tantly, the affinities for the two endogenous catecholamines confirm 
that the [125I]-ICYP binding sites indeed can be considered to be 
adrenoceptors. The biphasic competition curves for isoprenaline 
but not for noradrenaline or adrenaline in bladder (as in lung) most 
likely reflect agonist high and low affinity states of the receptor for 
the former, whereas the overall affinities of the latter two were too 
low to detect those. Although BRL 37,344 is often claimed to be a 
β
3
-selective agonist, our data demonstrate a similar affinity for this 
compound in rat bladder and lung. This is line with reports that BRL 
to demonstrate atypical β-adrenoceptors in rat soleus stri-
ated muscle (Roberts et al., 1993), but the binding sites iden-
tified in that study did not fully match the profile of cloned 
β
3
-adrenoceptors. Rat urinary bladder is a tissue which expresses 
all three β-adrenoceptor subtypes at the mRNA level (Fujimura 





-adrenoceptors contribute to smooth muscle relaxation, but 
the latter subtype appears to dominate functionally (Michel and 
Vrydag, 2006). While β
3
-adrenoceptors may play an even greater 





-population was deemed better suited for our purposes as it 
allows detection of the target subtype against a background of 
at least one other subtype.
For our radioligand binding studies we have used rat lung as a 
reference tissue, because this tissue lacks β
3
-adrenoceptor expres-





-adrenoceptors in an approximate 30:70% ratio 
(Minneman et al., 1979; Michel et al., 1987), and our present data, 
particularly with the β
1
-selective CGP 20,712A and the β
2
-selective 
ICI 118,551, confirm this observation. Moreover, our data show 
that definition of non-specific binding with 100 μM isoprenaline 
yields very similar saturation binding as isotherms as that by 1 μM 
propranolol in rat lung membranes. Hence, our rat lung data vali-
date our approach.
FIgurE 4 | Competition for [125I]-ICYP binding to rat urinary bladder by 
adrenergic agonists (upper panel) and antagonists (lower panel). Data are 
mean ± SEM of 4 to 8 experiments. Error bars have been omitted for clarity. 
Quantitative results are shown in Table 1.
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were very shallow in bladder (but not lung). Of note, Baker has 
recently reported a biphasic competition curve of non-iodinated 
cyanopindolol for [3H]-CGP 12,177 binding to β
3
-adrenoceptor-
expressing CHO cells (Baker, 2010). Finally, the high concentration 
of [125I]-ICYP required to label β-adrenoceptors in rat bladder were 
associated with a high non-specific binding (63% as compared 
to 24% in lung). This is a known phenomenon for its binding to 
cloned human β
3
-adrenoceptors, probably explained by the low 
affinity for β
3
-adrenoceptors as compared to a linear increase in 
non-specific binding with the required high radioligand concentra-
tions (Niclauß et al., 2006). The presence of such high non-specific 
binding is a problem as it generates low signal/noise ratios and 
hence can create problems in data analysis. This may also have 
contributed to the not fully explained competition curves with ICI 
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In conclusion, under assay conditions validated in rat lung, 
[125I]-ICYP can label specific and saturable binding sites in rat 
urinary bladder which in many ways resemble β
3
-adrenoceptors. 
However, the match in ligand recognition profile is incomplete 
and the high degree of non-specific binding associated with the 
required high concentrations of [125I]-ICYP limits interpretation of 
the data. These data support the idea that [125I]-ICYP at present is 
the only radioligand with at least limited suitability to label tissue 
β
3
-adrenoceptors, but better radioligands are clearly required to 
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37,344 basically lacks selectivity for cloned human β
3
-adrenoceptors 





-adrenoceptors (Mori et al., 2010). CGP 12,177 





et al., 2004; Baker, 2005), a low affinity agonist at the atypical site 
on the β
1
-adrenoceptor (Kaumann and Molenaar, 2008) and a 
low potency, partial agonist at β
3
-adrenoceptors (Baker, 2010). 
Its affinity found in the present study is in line with its reported 
β
3
-adrenoceptor affinity (Baker, 2010) but also with its potency at 
the low affinity site on β
1
-adrenoceptors (Kaumann and Molenaar, 
2008; Galindo-Tovar et al., 2009). However, all other drug affinities 
detected in our study are compatible with the labeling of a β
3
- but 
not a low affinity β
1
-site. Among the tested antagonists, propranolol, 
the β
1
-selective CGP 20,712A and the β
2
-selective ICI 118,551 all 
had affinities in line with reported values at β
3
-adrenoceptors 
(Hoffmann et al., 2004; Baker, 2005). The affinity estimated for 
non-iodinated cyanopindolol was also in line with reported values 
at β
3
-adrenoceptors (Baker, 2010). All of these data support the view 
that the specific binding sites labeled by high concentrations of 




However, there are a number of caveats which need to be 
considered. Firstly, the competition curves for ICI 118,551 were 
biphasic and included a minor (39%) fraction of sites with higher 
affinity. These sites could represent β
2
-adrenoceptors (Hoffmann 
et al., 2004; Baker, 2005), but that would raise the question why 
other compounds with high affinity for β
2
-adrenoceptors such as 
propranolol lacked a high affinity component in their competi-
tion curves. Secondly, SR 59,230A competed for more [125I]-ICYP 
sites than any other ligand tested here and hence also for many 
sites defined as non-specific based on isoprenaline competition. 
We do not know what these sites represent, but a low affinity 
[125I]-ICYP binding site insensitive, e.g., to BRL 37,344 has been 
reported in rat colon (Sugasawa et al., 1997). Thirdly, although non-
iodinated cyanopindolol competition curves were not significantly 
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